For how we live.
A pooled analysis puts patient-reported rates at 13.9%, 8.0% and 12.0%. All of it is self-report, the heterogeneity is enormous, and the reviewers stop short of recommending avoidance.
The older oral preventives managed 0.44 to 1.4. The larger change is that the new drugs work in people the old ones failed, and are tolerated well enough to stay taken.
A new structured dataset finally makes the approvals countable. Two trials published weeks apart show why counting them says little: 0.86 fewer migraine days in one, a 20-point symptom shift in the other.